Today announced it has selected an optimized Erk inhibitor molecule for advancement.

Related StoriesNew results reveal association between colorectal cancer and melanoma drug treatmentCrucial change in single DNA base predisposes kids to aggressive type of cancerNew RNA check of blood platelets can be used to detect area of cancerAn optimized Erk inhibitor compound, AEZS-140, and back-up candidates were defined as a total consequence of the development attempts. AEZS-140 and the back-up candidates demonstrate improved plasma publicity in rodents in addition to enhanced anti-tumor efficacy in comparison to the prior lead compound, AEZS-134. Furthermore, AEZS-140 was profiled against several medical Raf, Mek and Erk inhibitors and demonstrated extremely competitive activity. The Company will proceed with the next development methods for AEZS-140 and the back-up compounds, including in depth profiling in vitro and, also, further in vivo tumor versions.The ErbB receptors and their ligands in malignancy: a synopsis. Current Drug Targets.2005.  May;6:243-47. 10. Boyle P. Et al. World Cancer Survey 2008. International Company for Research on Tumor. *Afatinib and BIBF 1120 are investigational compounds; their security and efficacy have not been fully established.

Aged care needs an immediate boost By Dr Ananya Mandal, MD According to coalition of 28 groups, including medical researchers, unions and charitable organisations the aged-care system in Australia needs to be overhauled and improved in order to avoid an imminent crisis. They warn that the aged-care program, designed in the 1960s needs to be revamped. Yesterday launched the Australians Deserve to Age group Well campaign The coalition, to seek an overhaul of something that will have to support 3.5 million Australians by 2050.